{"id":786770,"date":"2023-09-28T10:45:00","date_gmt":"2023-09-28T14:45:00","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/"},"modified":"2023-09-28T10:45:00","modified_gmt":"2023-09-28T14:45:00","slug":"veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/","title":{"rendered":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023"},"content":{"rendered":"

<\/p>\n

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023<\/b><\/p>\n

SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE<\/a>)–Veracyte, Inc<\/a>. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company\u2019s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego.<\/p>\n

\nThe accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte\u2019s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, including the Decipher Prostate test.<\/p>\n

\n\u201cData that will be shared at this year\u2019s ASTRO meeting will demonstrate the Decipher Prostate test\u2019s ability to help clinicians make more informed treatment decisions based on the underlying biology of the individual patient\u2019s prostate cancer and will reinforce that prostate cancer molecular tests are not all created equal nor are they interchangeable,\u201d said Elai Davicioni, Ph.D., Veracyte\u2019s medical director for Urology. \u201cOur research collaborators will also present data derived from an analysis of the Decipher Genomics Research for Intelligent Discovery (GRID) database, which help advance understanding of the genomic mechanisms that drive treatment response.\u201d<\/p>\n

\nFollowing are details of the six presentations, which will all take place at the San Diego Convention Center:<\/p>\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n
Date\/Time:<\/i><\/td>\n\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nMonday, October 2, 2023, 3:10-3:16 p.m. PT<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nValidation of a Genomic Classifier in the NRG Oncology\/RTOG 0521 Phase III Trial of Docetaxel with Androgen Suppression and Radiotherapy for Localized High-Risk Prostate Cancer<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n158 (oral presentation)<\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nRyan Phillips, M.D., Ph.D., The Mayo Clinic<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nRoom 6 D\/E<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nMonday, October 2, 2023, 3:20-3:27 p.m. PT<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nCross-Comparison Individual Patient Level Analysis of Three Gene Expression Signatures in Localized Prostate in over 50,000 Men<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n159 (oral presentation)<\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nAngela Jia, M.D., Ph.D., Case Western Reserve University<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nRoom 6 D\/E<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nSunday, October 1, 2023, 4:55-5:02 p.m.<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nA Precision Medicine Navigator Can Mitigate Inequities Associated with Utilization of Genomic Tests in Black Men with Prostate Cancer<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n122 (oral presentation)<\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nAlexander Allen, M.D., University of Maryland Medical Center<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nRoom 4<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nMonday, October 2, 2023, 5:00-6:00 p.m. PT<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nLongitudinal Profiling of Tumor RNA Expression Signatures Reveal Key Biological Features Associated with Response to Neoadjuvant Stereotactic Body Radiation Therapy in High-Risk Prostate Cancer<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2539 (poster)<\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nAriel Marciscano, M.D., Massachusetts General Hospital<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nHall B2<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nTuesday, October 3, 2023, 2:30-3:45 p.m. PT<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nPredictive Value of Genomic Classifier Scores and Transcriptomic Data for Prostate Cancer Distant Metastasis Risk: A Multicenter Retrospective Study<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2926 (poster)<\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nJohn Nikitas, M.D., University of California Los Angeles (UCLA) Radiation Oncology<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nHall B2<\/p>\n<\/td>\n<\/tr>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n<\/tr>\n

\n

Date\/Time:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nTuesday, October 3, 2023, 2:30-3:45 p.m. PT<\/p>\n<\/td>\n<\/tr>\n

\n

Title:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nDynamic Changes of Molecular Subtype Classification and Genomic Classifier Scores in High-Risk Prostate Cancer Patients Undergoing Pre-Operative Stereotactic Body Radiation Therapy<\/p>\n<\/td>\n<\/tr>\n

\n

Abstract #:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n2825 (poster)<\/p>\n<\/td>\n<\/tr>\n

\n

Presenter:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nMarshall Diven, M.D., New York-Presbyterian Brooklyn Methodist Hospital<\/p>\n<\/td>\n<\/tr>\n

\n

Location:<\/i><\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\n\u00a0<\/p>\n<\/td>\n

\n

\nHall B2<\/p>\n<\/td>\n<\/tr>\n<\/table>\n

About Veracyte<\/b><\/p>\n

\nVeracyte (Nasdaq: VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our high-performing tests enable clinicians to make more confident diagnostic, prognostic, and treatment decisions for some of the most challenging diseases such as thyroid, prostate, breast, bladder and lung cancers, as well as interstitial lung diseases. We help patients avoid unnecessary procedures and speed time to diagnosis and appropriate treatment. In addition to making our tests available in the U.S. through our central laboratories, we also aim to deliver our tests to patients worldwide through a distributed model to laboratories that can perform them locally. Veracyte is based in South San Francisco, California. For more information, please visit www.veracyte.com<\/a> and follow the company on Twitter (@veracyte).<\/p>\n

Cautionary Note Regarding Forward-Looking Statements<\/b><\/p>\n

\nThis press release contains forward-looking statements, including, but not limited to our statements related to our plans, objectives, expectations (financial and otherwise) or intentions with respect to our clinical tests in and outside of the United States. Forward-looking statements can be identified by words such as: \u201cappears,\u201d “anticipate,” “intend,” “plan,” “expect,” “believe,” “should,” “may,” “will,” \u201cpositioned,\u201d \u201cdesigned\u201d and similar references to future periods. Examples of forward-looking statements include, among others, that the Decipher Prostate Genomic Classifier may help clinicians make more-informed treatment decisions based on the underlying biology of the individual patient\u2019s prostate cancer and that the Decipher GRID database data help advance understanding of the genomic mechanism that drives treatment response. Additional factors that may impact these forward-looking statements can be found under the caption \u201cRisk Factors\u201d in our Annual Report on Form 10-K filed on February 22, 2023, and our Quarterly Report on Form 10-Q filed for the three months ended June 30, 2023. Copies of these documents, when available, may be found in the Investors section of our website at https:\/\/investor.veracyte.com<\/a>. These forward-looking statements speak only as of the date hereof and, except as required by law, we specifically disclaim any obligation to update these forward-looking statements or reasons why actual results might differ, whether as a result of new information, future events or otherwise.<\/p>\n

\nDecipher Prostate is available in the U.S. as part of Veracyte\u2019s CLIA-validated laboratory developed test (LDT) service. This test has not been cleared or approved by the FDA. The Decipher GRID database is for Research Use Only. It is not for use to support treatment decisions.<\/p>\n

\nVeracyte, the Veracyte logo and Decipher are registered trademarks of Veracyte, Inc. and its subsidiaries in the U.S. and selected countries.<\/p>\n

\"\"<\/p>\n

View source version on businesswire.com: <\/span>https:\/\/www.businesswire.com\/news\/home\/20230928392023\/en\/<\/a><\/span><\/p>\n

Investors:
\n<\/b>
investors@veracyte.com
\n<\/a>
619-393-1545<\/p>\n

Media:
\n<\/b>
Tracy Morris
\n
VP of Global Corporate Communications
\n
tracy.morris@veracyte.com
\n<\/a>
650-380-4413<\/p>\n

KEYWORDS:<\/b> California United States North America<\/p>\n

INDUSTRY KEYWORDS:<\/b> Oncology Medical Supplies Health Medical Devices Hospitals Clinical Trials Biotechnology<\/p>\n

MEDIA:<\/b><\/p>\n\n\n\n\n
Logo<\/b><\/font><\/td>\n<\/tr>\n
\"Logo\"<\/td>\n<\/tr>\n
<\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"

Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company\u2019s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego. The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte\u2019s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, … <\/p>\n

Continue reading “Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-786770","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nVeracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company\u2019s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego. The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte\u2019s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, … Continue reading "Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2023-09-28T14:45:00+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"5 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023\",\"datePublished\":\"2023-09-28T14:45:00+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/\"},\"wordCount\":1037,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/\",\"name\":\"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en\",\"datePublished\":\"2023-09-28T14:45:00+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/","og_locale":"en_US","og_type":"article","og_title":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 - Market Newsdesk","og_description":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Veracyte, Inc. (Nasdaq: VCYT) announced that six abstracts highlighting new data from studies evaluating the company\u2019s Decipher Prostate Genomic Classifier and related capabilities will be presented, three as oral presentations, at the American Society for Radiation Oncology (ASTRO) Annual Meeting 2023 taking place October 1-4 in San Diego. The accepted abstracts include data from a large, randomized, phase 3 study that evaluated the ability of Veracyte\u2019s Decipher Prostate test to help inform treatment decisions among patients with high-risk prostate cancer, as well as a study that assessed risk-score correlation between the gene signatures of three commercially available genomic classifiers, … Continue reading \"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/","og_site_name":"Market Newsdesk","article_published_time":"2023-09-28T14:45:00+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"5 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023","datePublished":"2023-09-28T14:45:00+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/"},"wordCount":1037,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/","name":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023 - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en","datePublished":"2023-09-28T14:45:00+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&sty=20230928392023r1&sid=flmnd&distro=nx&lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/veracyte-announces-multiple-studies-reinforcing-the-value-of-decipher-prostate-testing-will-be-presented-at-astro-2023\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Veracyte Announces Multiple Studies Reinforcing the Value of Decipher Prostate Testing Will Be Presented at ASTRO 2023"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786770","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=786770"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/786770\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=786770"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=786770"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=786770"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}